²é¿´: 3434  |  »Ø¸´: 17
±¾Ìû²úÉú 1 ¸ö DRDEPI £¬µã»÷ÕâÀï½øÐв鿴

ronalbeck

Òø³æ (ÕýʽдÊÖ)


[½»Á÷] ÏÈÉùÒ©ÒµÒ»ÀàÐÂÒ©°¬À­ÄªµÂ»ñÅú ÒÑÓÐ15È˲ÎÓë

ÏÈÉùÒ©ÒµÒ»ÀàÐÂÒ©°¬À­ÄªµÂ»ñÅú  
2011-09-01  À´Ô´£ºÃ×ÄÚÍø   


      ºËÐÄÌáʾ£ºÏÈÉùÒ©Òµ¹«²¼Æä×ÔÖ÷Ñз¢µÄÖÎÁÆÀà·çʪÐԹؽÚÑ×ÐÂÒ©°¬À­ÄªµÂƬ (ÉÌÆ·Ãû£º°¬µÃÐÁ)Õýʽ»ñµÃ¹ú¼ÒʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨SFDA£©¹ú¼ÒÒ»ÀàÐÂÒ©Ö¤Êé¼°Ò©Æ·×¢²áÅúÎÄ¡£°¬µÃÐÁÊÇÈ«ÇòµÚÒ»¸öÉÏÊеݬÀ­ÄªµÂÖÆ¼Á¡£  

Ã×ÄÚÍø×¨¸å(Ñо¿Ô± Îâ¿¡½Ü)8ÔÂ24ÈÕ,ÏÈÉùÒ©ÒµÔÚÆä¹ÙÍø¹«²¼,Æä×ÔÖ÷Ñз¢µÄÐÂÒ©°¬À­ÄªµÂƬ (ÉÌÆ·Ãû:°¬µÃÐÁ)Õýʽ»ñµÃ¹ú¼ÒʳƷҩƷ¼à¶½¹ÜÀí¾Ö(SFDA)¹ú¼ÒÒ»ÀàÐÂÒ©Ö¤Êé¼°Ò©Æ·×¢²áÅúÎÄ¡£Åú×¼ÎĺÅΪ¹úÒ©×¼×ÖH20110084,¼ÁÐÍΪƬ¼Á,¹æ¸ñ25mg,ÏÈÉùҩҵͬʱ»ñµÃ°¬À­ÄªµÂµÄÔ­ÁÏÒ©ÅúÎÄ¡£

¾Ý½éÉÜ,°¬µÃÐÁÊÇÈ«ÇòµÚÒ»¸öÉÏÊеݬÀ­ÄªµÂÖÆ¼Á,Ò²ÊÇÒ»¸öȫнṹÀàÐ͵ÄDMARDS(Disease Modifying Anti-rheumatic Drugs,¼²²¡ÐÞÊο¹·çʪҩ)Ò©Îï,ÆäÖ÷ÒªÊÊӦ֢Ϊ»î¶¯ÐÔÀà·çʪÐԹؽÚÑ×,¿ÉÏÔÖø¸ÄÉÆÀà·çʪÐԹؽÚÑ×»¼Õߵļ²²¡Ö¢×´ºÍÑ×Ö¢Ö¸±ê,¼õÇỼÕßµÄÍ´¿à¡£

´ÓÃ×ÄÚÍø-»¯Ñ§Ò©ÁÙ´²ÓÃÒ©¾ºÕù¸ñ¾ÖÁ˽⵽,ÎÒ¹úÖÎÁÆÀà·çʪÐԹؽÚÑ×Ò©ÎïÖ÷ÒªÓа±»ùÆÏÌÑÌÇ¡¢Â¹¹Ï¶àëÄ¡¢·ú±ÈÂå·Ò¡¢ÈûÀ´Îô²¼µÈ,Êг¡¸ñ¾ÖÈçÏÂͼ¡£




½ñÄêÒÔÀ´,Óжà¸öÒ»ÀàÐÂÒ©»ñÅú,Ïà¹ØÇé¿öÈçϱí:

Ò©Ãû
¹«Ë¾
ÏêÇé

ÑÎËá°£¿ËÌæÄáÆ¬
±´´ïÒ©Òµ
Ò»ÀàÐÂÒ©ÑÎËá°£¿ËÌæÄáÉÏÊÐ

°¬ÈðÎô²¼Æ¬
ºãÈðÒ½Ò©
Ò»ÀàÐÂÒ©°¬ÈðÎô²¼»ñÅú

×¢ÉäÓÃÖØ×éÈËÄò¼¤Ã¸Ô­
ÉϺ£ÌìÊ¿Á¦Ò©Òµ
¶þ¼¾¶È¶à¸öÒ»ÀàÐÂÒ©»ñÉú²úÅúÎÄ

×¢ÉäÓÃÍ·æßÇúËÉÄÆÊæ°ÍÌ¹ÄÆ
Ïæ±±Íþ¶ûÂü
  

°¬À­ÄªµÂƬ
ÏÈÉùÒ©Òµ
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

ÌìȻҩÎﻯѧ ÎÒÐèÒªµÄÐÅÏ¢ ËÉÁÖҩͯ

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
2Â¥2011-09-01 14:22:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hardee

Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)

´Ë²ÝÓÐÖ÷~

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
zhychen2008(½ð±Ò+1, DRDEPI+1): ¶àлÌṩÐÅÏ¢ 2011-09-03 16:03:22


Meantime, Eisai and Toyama Chemical Co have submitted a marketing authorisation application  for T-614 (iguratimod), an anti-rheumatic agent being jointly developed in Japan by the two companies.

T-614 is a novel disease modifying anti-rheumatic drug originally discovered by Toyama and an MAA was previously submitted in 2003. However, the application was temporarily withdrawn in 2009 in order to conduct an additional clinical study which subsequently confirmed with statistical significance the efficacy of the agent as an add-on therapy for use with the standard of care, methotrexate.

http://www.pharmatimes.com/Artic ... epsy_portfolio.aspx

Ö»ÄÜ˵ÊÇÏÈÉùµÄÔËÆøºÃÁË¡£¡£¡£

[ Last edited by hardee on 2011-9-1 at 15:17 ]
°²µÃ´ÙÏ¥£¬¿É¹²Æ½Éú¡£
3Â¥2011-09-01 14:58:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zhenyu19

ľ³æ (СÓÐÃûÆø)

à½à½

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
¹úÍâûÅú£¬¹úÄÚÏÈÅúÁË£¿Õâ¾ÍÊÇ´«ËµÖеÄ1Àà°¡¡£
4Â¥2011-09-01 16:16:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Ò©µÀÈË

ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)

¾»ÓÉ»àÉú£¬Ã÷´Ó霳ö

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
zhychen2008(½ð±Ò+1): ¶àл²ÎÓë 2011-09-03 16:03:38
DMARDSÔçÒÑÊôÓÚ¶þÏßÓÃÒ©,ÓкÎÒâÒå
À´Ê±ºúͿȥʱÃÔ£¬¿ÕÔÚÈ˼ä×ßÕâ»Ø¡£Î´ÔøÉúÎÒË­ÊÇÎÒ£¬ÉúÎÒÖ®ºóÎÒÊÇË­£¿³¤´ó³ÉÈË·½ÖªÎÒ£¬ºÏÑÛëüëÊÓÖÊÇË­£¿²»Èç²»À´Ò²²»È¥£¬ÒàÎÞ·³ÄÕÒàÎÞ±¯¡£
5Â¥2011-09-02 09:48:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

dudu235

ľ³æ (ÖøÃûдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÏÈÉùºãÈð±´´ïÐÂÒ©Ñз¢ÒѾ­ÁìÏÈÁË Á˲»Æð Íþ¶ûÂüÔõôû̫Ìý˵¹ý£¿
ʱ¼äºã¾ÃÔ¶ËêÔ²»ÈÄÈË
6Â¥2011-09-02 10:28:20
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lpw106

Òø³æ (СÓÐÃûÆø)

»¹¿ÉÒÔ
7Â¥2011-09-02 11:03:19
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ö§³Ö°É£¡
8Â¥2011-09-02 11:04:45
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

1994yw

ľ³æ (ÕýʽдÊÖ)

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
zhychen2008(½ð±Ò+1): ¸Ðл»ØÌû½»Á÷ 2011-09-03 16:04:12
¶ÔÓÚ°¬À­ÄªµÂÕâ¸öËùνµÄÒ»ÀàÐÂÒ©£¬Ô¤¼ÆÎ´À´»¹ÓÐÁ½¸öÅúÎÄÏÂÀ´£¬¾Í¸ú¶÷Ìæ¿¨Î¤Ò»Ñù£¬12¸öÔÂÄÚÁ¬ÐøÅú³öÀ´Èý¸öÒ»ÀàÐÂÒ©¡£
ÕæÓÐÒâ˼£¡
9Â¥2011-09-02 11:06:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

iijs

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
»áÅúµØ£¬ÖØ´óרÏî´ÕÊýÒ²ÒªÅú¡£
10Â¥2011-09-02 11:50:16
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ ronalbeck µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 22408 344·Ö Çóµ÷¼Á Ò»Ö¾Ô¸ »ªµç¼ÆËã»ú¼¼Êõ +3 solanXXX 2026-03-20 3/150 2026-03-20 16:41 by fxue1114
[¿¼ÑÐ] 0817 »¯Ñ§¹¤³Ì 299·ÖÇóµ÷¼Á ÓпÆÑо­Àú ÓжþÇøÎÄÕ +21 rare12345 2026-03-18 21/1050 2026-03-20 14:31 by ÎÞи¿É»÷111
[¿¼ÑÐ] 0856µ÷¼Á£¬ÊÇѧУ¾ÍÈ¥ +8 sllhht 2026-03-19 9/450 2026-03-20 14:25 by ÎÞи¿É»÷111
[¿¼ÑÐ] ²ÄÁÏѧ˶297ÒѹýËÄÁù¼¶Çóµ÷¼ÁÍÆ¼ö +6 adaie 2026-03-19 6/300 2026-03-20 14:12 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ÉúÎïѧµ÷¼ÁÕÐÈË£¡£¡£¡ +3 ɽº£Ììá° 2026-03-17 4/200 2026-03-19 21:34 by ÔõôÊÍ»³
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +4 18889395102 2026-03-18 4/200 2026-03-19 16:13 by 30660438
[¿¼ÑÐ] 085601²ÄÁϹ¤³Ìר˶Çóµ÷¼Á +10 Ľº®mio 2026-03-16 10/500 2026-03-19 15:26 by ¶¡¶¡*
[¿¼ÑÐ] 286Çóµ÷¼Á +6 lemonzzn 2026-03-16 10/500 2026-03-19 14:31 by lemonzzn
[¿¼ÑÐ] 328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑо­Àú +4 ÉúÎ﹤³Ìµ÷¼Á 2026-03-16 12/600 2026-03-19 11:10 by ÉúÎ﹤³Ìµ÷¼Á
[¿¼ÑÐ] 295Çóµ÷¼Á +3 Ò»Ö¾Ô¸¾©Çø211 2026-03-18 5/250 2026-03-18 17:03 by zhaoqian0518
[¿¼ÑÐ] ÊÕ¸´ÊÔµ÷¼ÁÉú +4 ÓêºóÇïºÉ 2026-03-18 4/200 2026-03-18 14:16 by elevennnne
[¿¼ÑÐ] 268Çóµ÷¼Á +8 Ò»¶¨ÓÐѧÉÏ- 2026-03-14 9/450 2026-03-17 17:47 by laoshidan
[¿¼ÑÐ] ²ÄÁÏר˶326Çóµ÷¼Á +6 Ä«ìÏæ¦Ý· 2026-03-15 7/350 2026-03-17 17:10 by ruiyingmiao
[¿¼ÑÐ] 085601Çóµ÷¼Á +4 Du.11 2026-03-16 4/200 2026-03-17 17:08 by ruiyingmiao
[¿¼ÑÐ] ²ÄÁÏÓ뻯¹¤×¨Ë¶µ÷¼Á +5 heming3743 2026-03-16 5/250 2026-03-17 14:03 by Ó¸ÒÌ«¼àÍõ¹«¹«
[¿¼ÑÐ] 326Çóµ÷¼Á +4 ŵ±´¶û»¯Ñ§½±êéê 2026-03-15 7/350 2026-03-16 17:11 by ŵ±´¶û»¯Ñ§½±êéê
[»ù½ðÉêÇë] ½ñÄêµÄ¹ú»ù½ðÊÇ´ò·ÖÖÆÂ𣿠50+3 zhanghaozhu 2026-03-14 3/150 2026-03-16 17:07 by ±±¾©À³ÒðÈóÉ«
[¿¼ÑÐ] 277²ÄÁÏ¿ÆÑ§Ó빤³Ì080500Çóµ÷¼Á +3 ×ÔÓɼå±ý¹û×Ó 2026-03-16 3/150 2026-03-16 14:10 by ÔËÆøyunqi
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á 290·ÖÓпÆÑо­Àú£¬ÂÛÎÄÔÚͶ +7 ÄåÄågk 2026-03-14 7/350 2026-03-16 10:12 by houyaoxu
[¿¼ÑÐ] 327Çóµ÷¼Á +6 ʰ¹âÈÎȾ 2026-03-15 11/550 2026-03-15 22:47 by ʰ¹âÈÎȾ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û